Key result
PLA2G7 V379 allele is linked to a lower risk of future cardiovascular events.
Why the study?
PAF-AH activity has been postulated as a risk factor for CAD, but its causal role versus marker status remains unclear.
Does the PLA2G7/A379V polymorphism reduce the risk of future cardiovascular events in patients with coronary artery disease?
Population
1314 CAD patients and 485 healthy controls
Comparison
PLA2G7 and PTAFR gene polymorphisms including PLA2G7/A379V allele variants
Design
Prospective cohort study with haplotype analyses
Authors
Loading...
PLA2G7 V379 may mark lower CAD risk; leaves open whether PAF-AH activity modulates events or remains a noncausal marker.
Cohort (n=1,799)
Does the PLA2G7/A379V polymorphism reduce the risk of future cardiovascular events in patients with coronary artery disease?
The V379 allele of the PLA2G7 gene may confer a protective effect against the development of coronary artery disease and subsequent cardiovascular events.
Ewa Ninio (2004) conducted a cohort in Coronary artery disease (n=1,799). PLA2G7/A379V polymorphism (V379 allele) vs. Non-carriers / other alleles was evaluated on Risk of CAD and future cardiovascular events. The V379 allele of the PLA2G7 gene was less frequent in CAD patients than controls and was associated with a lower risk of future cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: